Literature DB >> 15616809

Progressive multifocal leukoencephalopathy in transplant recipients.

David Shitrit1, Nirit Lev, Ariella Bar-Gil-Shitrit, Mordechai R Kramer.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating infection caused by the JC virus. It is an emerging disease in transplant recipients; however, it remains poorly defined. Twenty-four cases of PML reported in the literature in transplant recipients were reviewed. Of the 24 cases, nine occurred in renal, six in bone marrow, four in liver, three in heart and two in lung transplant recipients. Median time to onset was 17 months; 71% occurred within 24 months of transplantation. PML tended to occur later in the kidney recipients (P=0.04). Seventy-five percent had subacute presentation; hemiparesis (50%), apathy (46%) and confusion (38%) were the most frequently presented features. Treatment included reduction of immunosuppression and chemotherapy, mainly cidofovir. Death occurred within 2.5 months of the onset of symptoms in 17 patients (71%). PML is a unique entity that should be considered in any transplant recipient with neurological symptoms. The outcome is usually fatal, although regression has been reported.

Entities:  

Mesh:

Year:  2004        PMID: 15616809     DOI: 10.1007/s00147-004-0779-3

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  40 in total

1.  JC Virus Infection After Transplantation: Beyond the Classic Progressive Multifocal Leukoencephalopathy?

Authors:  Supha Kijpittayarit; Raymund R Razonable
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-01

2.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Ozgür Yaldizli; Norman Putzki
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation.

Authors:  Lora D Thomas; Aaron P Milstone; Regis A Vilchez; Preeti Zanwar; Janet S Butel; J Stephen Dummer
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

Review 4.  Emerging viral infections of the central nervous system: part 2.

Authors:  Kenneth L Tyler
Journal:  Arch Neurol       Date:  2009-09

5.  JC virus infection of the brain.

Authors:  A K Bag; J K Curé; P R Chapman; G H Roberson; R Shah
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

Review 6.  An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases.

Authors:  Alice S Appel; Gerald B Appel
Journal:  Nat Clin Pract Nephrol       Date:  2009-01-27

7.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

Review 8.  Infectious agents and colorectal cancer: a review of Helicobacter pylori, Streptococcus bovis, JC virus, and human papillomavirus.

Authors:  Andrea N Burnett-Hartman; Polly A Newcomb; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

9.  Unmasking of PML by HAART: unusual clinical features and the role of IRIS.

Authors:  Navdeesh Sidhu; J Allen McCutchan
Journal:  J Neuroimmunol       Date:  2009-12-04       Impact factor: 3.478

10.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Authors:  B O Khatri; S Man; G Giovannoni; A P Koo; J-C Lee; B Tucky; F Lynn; S Jurgensen; J Woodworth; S Goelz; P W Duda; M A Panzara; R M Ransohoff; R J Fox
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.